Stock FOLLI FOLLICUM AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Follicum AB (publ) Share Price

Equities

FOLLI

SE0006288270

Biotechnology & Medical Research

Chart Follicum AB (publ)

Dynamic Chart

Latest news about Follicum AB (publ)

Coegin Pharma AS completed the acquisition of Follicum AB. CI
Follicum AB Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Follicum AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Coegin Pharma AS agreed to acquire Follicum AB for SEK 35.4 million. CI
Follicum AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Follicum AB Reports Revised Top-Line Results from the Phase IIa study of FOL-005 for the Treatment of Hair Loss CI
Follicum AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Follicum AB Announces Executive Changes CI
Follicum AB Reports Top-Line Results from Phase IIa Study of FOL-005 for Treatment of Hair Loss CI
Follicum Announces CEO Changes CI
Follicum AB Establishes New Role as Chief Scientific Officer CI
Follicum AB Announces New Preclincial Study Confirms Mechanism of Action of its Novel Tissue Repair Peptides CI
Follicum AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020 CI
Follicum AB Reports That All Patients Have Completed Treatment with FOL-005 in the Phase II Study Against Hair Loss CI
Follicum AB Announces All Patients Included in the Ongoing Ase IIa Clinical Study with itits Lead Drug Candidate FOL-005 CI
More news

Press releases Follicum AB (publ)

BioStock: Coegin Pharma fuses with Swedish biotech Follicum AQ
Follicum : har avslutat sin likviditetsgaranti från Sedermera Fondkommission rörande handeln i aktien PU
Follicum : reports revised top-line results from the Phase IIa study of FOL-005 for the treatment of hair loss (alopecia) AQ
BioStock article: Hopeful stock surge in Follicum after suspected analysis error in hair loss project PU
BioStock: Hopeful stock surge in Follicum after suspected analysis error in hair loss project AQ
More press releases

Managers and Directors - Follicum AB (publ)

Managers TitleAgeSince
Jonas Erik Edelswärd CEO
 Chief Executive Officer 65 09/05/21
Maria Ekblad CTO
 Chief Tech/Sci/R&D Officer - 31/12/15
Members of the board TitleAgeSince
Alejandra Maria Mørk BRD
 Director/Board Member 62 31/12/17
Gun-Britt Fransson CHM
 Chairman 71 31/12/17
Carl-Johan Spak BRD
 Director/Board Member 68 26/09/19
More insiders

Company Profile

Follicum AB is a Sweden-based biopharmaceutical company. The Company develops pharmaceutical treatments to control hair growth. It focuses on both drugs to inhibit and stimulate hair growth. The Company's main drug candidate for hair growth inhibition, FOL-005, is based on an endogenous protein. Its drug candidates for hair growth stimulation, are based on an endogenous protein that is broken down by the body.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.20% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FOLLI Stock